HC Wainwright Expects Reduced Earnings for Maze Therapeutics

Posted by George Bondi on Nov 12th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Analysts at HC Wainwright decreased their FY2026 EPS estimates for Maze Therapeutics in a research note issued on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($2.86) for the year, down from their prior estimate of ($2.63). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.72) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($2.55) EPS, FY2029 earnings at ($2.39) EPS and FY2030 earnings at ($2.52) EPS.

MAZE has been the subject of a number of other reports. Canaccord Genuity Group started coverage on Maze Therapeutics in a report on Monday, October 19th. They set a “buy” rating and a $75.00 price objective for the company. Citigroup began coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Wedbush upped their price objective on Maze Therapeutics from $48.00 to $49.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average target price of $63.91.

Read Our Latest Research Report on Maze Therapeutics

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $36.73 on Thursday. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -13.86 and a beta of 2.04. The stock’s 50 day moving average is $28.32 and its 200-day moving average is $31.63. The company has a quick ratio of 18.31, a current ratio of 14.14 and a debt-to-equity ratio of 0.09. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01).

Insider Buying and Selling

In other Maze Therapeutics news, CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the sale, the chief executive officer owned 18,151 shares of the company’s stock, valued at $477,189.79. This trade represents a 65.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at approximately $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 176,849 shares of company stock worth $4,741,878 over the last ninety days. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MAZE. Sterling Capital Management LLC increased its stake in Maze Therapeutics by 390.5% in the 3rd quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock worth $30,000 after purchasing an additional 867 shares during the period. Royal Bank of Canada increased its holdings in Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics during the 2nd quarter valued at about $48,000. Quantbot Technologies LP bought a new position in Maze Therapeutics during the 2nd quarter valued at approximately $80,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Maze Therapeutics during the 3rd quarter valued at approximately $77,000.

Recent Maze Therapeutics Headlines

Here are a few of the latest headlines about MAZE:

Positive Sentiment: Wedbush reportedly expects MAZE shares to rise, adding a bullish analyst view. Maze Therapeutics stock price expected to rise, Wedbush analyst says
Neutral Sentiment: JPMorgan lowered its price target to $51 from $53 but maintained an “overweight” rating, signaling continued optimism alongside a more cautious valuation. JPMorgan lowers Maze Therapeutics price target
Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2030 and several 2027 quarters, projecting larger losses than previously expected. It nevertheless kept its “Buy” rating and $110 price target. The reduced estimates are a potential near-term headwind. Maze Therapeutics analyst estimates and ratings

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.